Combining immune checkpoint inhibitors with standard treatment regimens in advanced human epidermal growth factor receptor-2 positive gastric cancer patients

Figure 1 Comparison of objective response rate and disease control rate between control and observation groups, immunohistochemistry 3 + patients, and programmed death-ligand 1-positive patients, arranged in a grid format. A: Comparison of objective response rate (ORR) and disease control rate (DCR) between control and observation groups; B: Comparison of ORR and DCR for immunohistochemistry 3 + patients; C: Comparison of ORR and DCR for programmed death-ligand 1-positive patients. ORR: Objective response rate; DCR: Disease control rate; IHC: Immunohistochemistry; PD-L1: Programmed death-ligand 1.

Figure 2 Progression-free survival curves. A: The control and observation groups; B: Immunohistochemistry 3 + patients in the control and observation groups; C: Programmed death-ligand 1 expression in the observation group. PD-L1: Programmed death-ligand 1.